News
Allon shareholders approve balance of October prospectus financing
VANCOUVER, B.C. — Allon Therapeutics Inc.(TSX: NPC), today announced that its shareholders have approved the investment by Neuro Discovery II Limited Partnership (“ND II LP”) which was made as part of its October 2011 prospectus offering. The prospectus offering resulted in gross proceeds of $5... Continue reading
Posted in News Releases
Allons intellectual property portfolio strengthened with additional U.S. patent
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted a United States patent covering the use of Allon’s drug candidates, including its lead product davunetide, and other pipeline products, for the treatment of laser induced retinal damage. This new patent... Continue reading
Posted in News Releases
Allon invited to present at two major conferences
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley has been invited to present an update of the Company’s business progress on Tuesday, November 29, 2011 at the Piper Jaffray Health Care Conference in New York City. McCauley’s presentation will include an upda... Continue reading
Posted in News Releases
Allon Therapeutics releases Q3 operating results and provides corporate update
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) today announced its unaudited operating results for the three and nine month periods ended September 30, 2011. Allon also said that two events subsequent to the end of the Third Quarter have kept the Company on track to achieve its objective of... Continue reading
Posted in News Releases
Allon's CEO presenting at BIO Investor Forum
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress on Wednesday, October 26 at the 10th Annual BIO Investor Forum in San Francisco attended by public and private equity investors, research analysts, inv... Continue reading
Posted in News Releases